Ligand Buys Xoma for $740M, Accelerates Royalty Aggregation Strategy

What happened

Ligand Pharmaceuticals announced the acquisition of fellow royalty aggregator Xoma for nearly $740 million, a significant deployment of its ~$1B capital war chest. The deal combines two companies known for investing in drug development-stage assets to collect royalties on future sales, creating a larger royalty portfolio. However, the acquisition consumes a large portion of Ligand's deployable capital, potentially reducing near-term flexibility for additional deals. The move comes as Ligand trades at elevated multiples (78.9x P/E), pricing in successful execution of its 2026 royalty guidance of $200M-$225M. Integration risks and the need to maintain underwriting discipline add uncertainty to the already concentrated royalty growth story centered on FILSPARI and Ohtuvayre.

Implication

Over the long term, the deal accelerates Ligand's royalty aggregation model and could diversify its portfolio beyond FILSPARI and Ohtuvayre, but investors must monitor whether the acquisition delivers accretive returns and whether management maintains discipline in future deployments.

Thesis delta

The Xoma acquisition shifts Ligand's thesis from a 'wait for proof of royalty acceleration' to 'accelerated deployment at a price.' While it validates the redeployment strategy, it also consumes a large portion of deployable capital and introduces integration risk, raising the bar for future royalty growth to justify the premium valuation.